Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

What the Steady First Half Means for EKF Diagnostics Holdings (LSE:EKF)

EKF operates in two broad areas. Its Point-of-CareBusinessmakes analysers and tests used in clinics and hospitals, including beta-hydroxybutyrate (β-HB) measurement products. Its Life Sciences business produces enzymes and other materials through fermentation, including at itsFacilityin south Wales, and the group also offers contract manufacturing.

Ankur Sharma | 16 November 2026

How 4basebio (LSE: 4BB) raised about £15m to fund its synthetic DNA ambitions in the FTSE AIM All Share Index

4basebio is a biotechnology company that uses synthetic DNA for next-generation therapeutics and vaccines. Its proprietary enzymatic DNA synthesis platform produces GMP-grade synthetic DNA and mRNA. The company supplies DNA constructs for gene therapies, genome editing, mRNA production and DNA vaccines. Amy Walker is …

Ishan Mudgal | 16 November 2026

How Abingdon Health (LSE: ABDX) narrowed losses as it expands in the US within the FTSE AIM All Share Index

Abingdon Health specialises in lateral flow diagnostic tests, the rapid test format familiar to many people from the pandemic. It offers contract development andManufacturingservices, helping other companies design, scale up and produce tests, and it also provides regulatory and related support. The company is …

Ishan Mudgal | 16 November 2026

What H.B. Fuller's Agreed Takeover Means for Advanced Medical Solutions (LSE: AMS) and the FTSE AIM All Share Index

AMS describes itself as a tissue-healing technology company. It makes surgical products, including tissue adhesives, sutures and biosurgical devices, as well as woundcare dressings. Surgical is now the larger of its two divisions, boosted by the acquisition of Peters Surgical in July 2024. The …

Ishan Mudgal | 16 November 2026

How Anpario (LSE: ANP) is growing earnings within the FTSE AIM All Share Index

Anpario produces and sells natural feed additives intended to support animal health, nutrition and biosecurity for livestock producers. Its products are sold internationally, and the company regularly highlights the geographic diversity of its customer base as a strength. That spread of markets means results …

Ishan Mudgal | 16 November 2026

What a proposed Medicare coverage decision means for AOTI, Inc. (LSE: AOTI) in the FTSE AIM All Share Index

AOTI develops and supplies TWO2 therapy, a topical oxygen treatment for chronic wounds such as diabetic foot ulcers. The company is US-focused and its shares trade on AIM in London. Its commercial model depends heavily on reimbursement from US public and private payers, which …

Ishan Mudgal | 16 November 2026

What Aptamer Group's (LSE: APTA) New Partnership Means for Its Optimer Strategy in the FTSE AIM All Share Index

Aptamer Group is a UK-based biotechnology company that develops Optimer binders, synthetic molecules that recognise and bind to specific targets in a similar way to antibodies. The company works with pharmaceutical, diagnostics and life science customers, earning fees for discovery and development work and, …

Ishan Mudgal | 16 November 2026

What Arecor Therapeutics' new funding and patents mean for its FTSE AIM All Share Index story (LSE: AREC)

Arecor is a clinical-stage biotechnology company based in Cambridge and quoted on AIM. It focuses on therapies for diabetes, obesity and other cardiometabolic diseases. Its two insulin candidates are AT278, an ultra-concentrated, ultra-rapid-acting insulin at 500 units per millilitre, and AT290, a concentrated ultra-rapid …

Ishan Mudgal | 16 November 2026

Abingdon Health (LSE:ABDX): New Diagnostics Partnership Puts This FTSE AIM All-Share Small-Cap Growth Stock Back in Focus

• The next major catalyst is commercialisation, manufacturing scale-up, customer wins, US expansion and cash use.

Ankur Sharma | 16 November 2026

Cambridge Cognition (LSE:COG): Digital Cognitive Testing Demand Puts This FTSE AIM All-Share Small-Cap Growth Stock in Focus

• The next major catalyst is contract wins, recurring software revenue, pharmaceutical customers and cash generation.

Ankur Sharma | 16 November 2026
Support

Hi! How can we help you today?

Loading…